BMS-986224   Click here for help

GtoPdb Ligand ID: 11838

Synonyms: BMS986224
Compound class: Synthetic organic
Comment: BMS-986224 is an orally bioavailable small molecule apelin receptor agonist that was selected as a clinical lead with potential to treat heart failure [1-2]. Clinical development was discontinued at Phase 1.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 132.59
Molecular weight 498.13
XLogP 4.49
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOCc1[nH]c(=O)c(c(c1c1c(OC)cccc1OC)O)c1nnc(o1)Cc1ccc(cn1)Cl
Isomeric SMILES CCOCc1c(c(c(c(=O)[nH]1)c1nnc(o1)Cc1ncc(cc1)Cl)O)c1c(cccc1OC)OC
InChI InChI=1S/C24H23ClN4O6/c1-4-34-12-15-19(20-16(32-2)6-5-7-17(20)33-3)22(30)21(23(31)27-15)24-29-28-18(35-24)10-14-9-8-13(25)11-26-14/h5-9,11H,4,10,12H2,1-3H3,(H2,27,30,31)
No information available.
Summary of Clinical Use Click here for help
Phase 1 clinical evaluations of BMS-986224 have been completed. Development appears to have been discontinued.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03634969 An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants Phase 1 Interventional Bristol-Myers Squibb
NCT03563950 An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants Phase 1 Interventional Bristol-Myers Squibb
NCT03281122 A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction Phase 1 Interventional Bristol-Myers Squibb